MedTrace Logo

Senescent Immunity in Elders and Vaccine Responses (SILVER)

NCT04077424 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-07-12

Study results available
· View outcomes & findings →

Summary

To study the effects of age on the immune system's response to flu vaccine and to study the connection between the immune system and physical and cognitive changes associated with aging.

Conditions

  • Flu Vaccine

Interventions

BIOLOGICAL

Fluzone-High Dose Quadrivalent

Seasonal influenza vaccination with FDA approved vaccines for this age group.

BIOLOGICAL

Fluad

Adjuvanted (MF59) inactivated influenza vaccine

BIOLOGICAL

Flublock

Recombinant hemagglutinin vaccine

Sponsors & Collaborators

  • Vanderbilt University Medical Center

    lead OTHER

Principal Investigators

  • Spyros Kalams · Vanderbilt University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Max Age
125 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-21
Primary Completion
2020-02-01
Completion
2020-02-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04077424 on ClinicalTrials.gov